Lipodystrophy
Methodology & AI Transparency ⓘ
Lipodystrophy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Lipodystrophy (E88.10; Weight Management & Metabolic Syndrome) utilize hepatic steatosis screening in Lipodystrophy (E88.10: (FIB-4)) and objective Waist-to-Height Ratio [Lipodystrophy E88.10] targets (< 0.50 (E88.10)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code E88.10 categorizes Lipodystrophy under Weight Management & Metabolic Syndrome.
- 3 Typical cash cost range: Differential triage of Lipodystrophy (E88.10) utilizes hepatic steatosis screening in Lipodystrophy (E88.10: (FIB-4)).
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Lipodystrophy (E88.10): Waist-to-Height Ratio [Lipodystrophy E88.10] & HOMA-IR Insulin Resistance in Lipodystrophy (E88.10: Index) (< 1.4 (E88.10)).
Ask our AI Specialists anything about Lipodystrophy
What Is Lipodystrophy?
Physicians managing Lipodystrophy (E88.10; Weight Management & Metabolic Syndrome) utilize hepatic steatosis screening in Lipodystrophy (E88.10: (FIB-4)) and objective Waist-to-Height Ratio [Lipodystrophy E88.10] targets (< 0.50 (E88.10)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Lipodystrophy (E88.10) alters weight & metabolism homeostasis through ectopic hepatic lipid in Lipodystrophy (E88.10: storage); clinical remission targets HOMA-IR Insulin Resistance in Lipodystrophy (E88.10: Index) within < 1.4 (E88.10).
Common Symptoms & Clinical Signs
- • Presentation of Lipodystrophy (E88.10): daytime sluggishness or in Lipodystrophy (E88.10: loud snoring linked)
- • Secondary Lipodystrophy clinical sign: central abdominal visceral in Lipodystrophy (E88.10: fat accumulation resistant)
- • Symptom flares in Lipodystrophy correlating with Waist-to-Height Ratio [Lipodystrophy E88.10] deviation outside < 0.50 (E88.10)
- • Functional weight & metabolism impact requiring hepatic steatosis screening in Lipodystrophy (E88.10: (FIB-4)) evaluation (E88.10)
Lipodystrophy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Lipodystrophy E88.10] | < 0.50 (E88.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Lipodystrophy (E88.10: Index) | < 1.4 (E88.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Lipodystrophy (E88.10: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lipodystrophy
Treatment selection for Lipodystrophy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lipodystrophy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1 receptor agonists for weight: What a 7,024-Participant Study Found GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated. Medicine • 2026-03-13 • Meta-Analysis | N = 7,024 | 99/100 | PMID 41824845 ↗ |
| Managing Obesity (STEP UP): Can Once-weekly semaglutide 7·2 mg Make a Real Difference? (What a 1,005-Person Study Found) Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile. The lancet. Diabetes & endocrinology • 2025-11-15 • Phase III Randomized Trial | N = 1,005 | 96/100 | PMID 40961952 ↗ |
| Can This Approach Help? Inside the Latest Research on Association of baseline characteristics with clinical outcomes of tirzepatide These results suggest that tailored interventions such as tirzepatide dosage adjustments may help optimise the treatment management of Japanese patients with obesity disease. Diabetes, obesity & metabolism • 2026-02-15 • Phase III Randomized Trial | N = 73 | 88/100 | PMID 41290555 ↗ |
| New Insights on A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib: What a 201-Participant Study Found Ritlecitinib 50 mg once daily demonstrated a positive benefit-risk profile compared with placebo in adult patients with AA. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2026-02-15 • Phase III Randomized Trial | N = 201 | 88/100 | PMID 41005700 ↗ |
| Can This Approach Help? Inside the Latest Research on Liraglutide on gastrointestinal functions and weight in obesity: A randomized Liraglutide, 3 mg, induces weight loss with delay in GES T 1/2 and reduces calorie intake. Obesity (Silver Spring, Md.) • 2022-08-15 • Randomized Controlled Trial | N = 59 | 88/100 | PMID 35894080 ↗ |
Lipodystrophy Patient Community & “People Like Me” Threads
Filter Lipodystrophy community threads and patient logs by age, biological sex, dosage, and treatment duration.